Non-invasive Prenatal Testing (NIPT) Market – 2019 Advanced Technology, Industry Size, Future Trends, Regional Share Analysis by Top Key Player Developments and Demand Penetration, Forecast to 2026

Noninvasive Prenatal Testing (NIPT) Market – Insights

Noninvasive prenatal testing (NIPT), also known as noninvasive prenatal screening (NIPS), aids to determine the risk that the fetus will be born with certain genetic abnormalities such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). NIPS can also be used in determining the gender of the fetus. The approach is widely used in diagnosis of Down syndrome. NIPS aids in decision making on various diagnostic tests such as chorionic villus sampling (CVS) or collected from the amniotic fluid or placenta, in order to determine the presence of chromosome abnormality in infants. NIPS can be performed any time after 9 weeks into pregnancy, earlier than any other prenatal screening or diagnostic test. In NIPS, DNA from the mother and fetus is extracted from maternal blood sample.

Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Non-invasive Prenatal Testing, https://www.coherentmarketinsights.com/insight/request-pdf/579

NIPS is recommended for women with high risk of chromosomal disorder in infants due to older maternal age or previous child suffering from Down syndrome, trisomy 13 or trisomy 18. The test is also recommended when a woman has an Rh negative blood type. The mother might produce Rh antibodies after exposure to fetal red blood cells if the fetus has Rh positive blood type. This scenario is not a concern during a first pregnancy, but during subsequent pregnancies.

Noninvasive Prenatal Testing Market Taxonomy

By Product Type

• Assay Kits & Reagents
• Consumables
• Disposables
• Next-Generation Sequencing System
• Instruments
• PCR Instruments
• Ultrasound Devices
• Microarrays
• Other Instruments

By Method

• Ultrasound Detection
• Cell-free DNA in Maternal Plasma Tests
• Biochemical Screening tests
• Fetal Cells in Maternal Plasma Tests

By Application

• Trisomy
• Micro deletion Syndrome
• Other Application

By End User

• Diagnostic Laboratories
• Hospitals

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/non-invasive-prenatal-testing-nipt-market-579

Noninvasive Prenatal Testing Market: Drivers

Increasing number of women opting for late pregnancies is expected to augment growth of the non-invasive prenatal testing market. Increasing number of working women has led to increase in the average maternal age, which increases risk of infants born with Down syndrome. Other factors that influence the scenario include, the number of existing siblings and the gap between the child and his immediate preceding sibling. For instance, according to the Centers for Disease Control and Prevention, 2016, Down syndrome continues to be the most common chromosomal disorder, as around 6000 newborns suffer from Down syndrome in the U.S., annually. According to the same source, 2017, older mothers are more likely to have an infant suffering from Down syndrome compared to younger mothers.

Noninvasive Prenatal Testing Market: Regional Analysis

North America is expected to account for the largest market share over the forecast period. This is attributed to increasing cases of chromosomal abnormalities and increasing maternal age.

The market in Asia Pacific is driven by factors such as increasing disposable income, developing healthcare infrastructure, and increasing awareness regarding NPIT.

The market in various other regions is driven by high level of safety and guarantee offered with NIPT.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/579

Noninvasive Prenatal Testing Market: Competitive Landscape

Key players in the market are focused on adopting M&A strategies in order to expand their product portfolio. For instance, in January 2017, LabCorp acquired Sequenom Inc.

Major players operating the global non-invasive prenatal testing market include F. Hoffmann-La Roche Ltd., Pacific Biosciences of California, Inc., GE Healthcare, Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.